Communiqués Chimeric Therapeutics Limited

Actions

Marché Fermé - Australian S.E. Autres places de cotation 08:10:57 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,018 ^AUD	0,00 %		0,00 %	-48,57 %

22/05	L'étude CHM CDH17 de Chimeric Therapeutics, première étude chez l'homme, est ouverte au recrutement ; les actions progressent de 4 %.	MT
02/05	Chimeric Therapeutics nomme un directeur de l'exploitation ; les actions augmentent de 4 %.	MT

Chimeric Therapeutics To Attend BIO International Convention	05/06/23	AQ
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial	05/06/23	AQ
Chimeric Therapeutics thrilled with ethics approval for brain cancer study	27/04/23	AQ
Chimeric Therapeutics : Application for quotation of securities - CHM	15/06/22	PU
Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies	12/04/22	GL
Chimeric Therapeutics : Appendix 2A	25/03/22	PU
Chimeric Therapeutics : Appendix 3B (amended)	08/03/22	PU
Chimeric Therapeutics : CORE NK Platform Phase 1 Clinical Data Presentation	06/03/22	PU
Chimeric Therapeutics : Appendix 3B (amended)	22/02/22	PU
Chimeric Therapeutics : Investor Presentation - Entitlement Offer	22/02/22	PU
Chimeric Therapeutics : Prospectus	21/02/22	PU
Chimeric Therapeutics : Appendix 3B	21/02/22	PU
Chimeric Therapeutics : Notification regarding unquoted securities - CHM	06/02/22	PU
Chimeric Therapeutics : Change of Director's Interest Notice - JC, CE & GM	14/12/21	PU
Chimeric Therapeutics : Application for quotation of securities - CHM	06/12/21	PU
Chimeric Therapeutics : Notification regarding unquoted securities - CHM	03/12/21	PU
Chimeric Therapeutics : Application for quotation of securities - CHM	03/12/21	PU
Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform	01/12/21	GL
Chimeric Therapeutics : Transformative Portfolio Expansion Presentation	30/11/21	PU
Chimeric Therapeutics : AGM Presentation	21/11/21	PU

Aucun résultat pour cette recherche